Prova Education: Changing the Practice of Medicine

Changing the Practice of Medicine

Discover CME, tools, and guideline-focused education to
improve your knowledge - and patient outcomes.

Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
1.00 program credit
- Hong Zhang
1.00 program credit
Emerging Therapies in IgAN: Who Could Benefit the Most?
Emerging Therapies in IgAN: Who Could Benefit the Most?
MinuteCE®
Emerging Therapies in IgAN: Who Could Benefit the Most?
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
Emerging Evidence: IgAN Disease-Modifying Agents
Emerging Evidence: IgAN Disease-Modifying Agents
MinuteCE®
Emerging Evidence: IgAN Disease-Modifying Agents
1.00 program credit
- Richard Lafayette, MD, FACP
- Hong Zhang
1.00 program credit
IgAN SOC: Strengths and Limits
IgAN SOC: Strengths and Limits
MinuteCE®
IgAN SOC: Strengths and Limits
1.00 program credit
- Dana Rizk, MD
- Suzuki Yusuke, MD, PhD
1.00 program credit
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
MinuteCE®
Translating Guidelines to Action in IgAN: Embracing a Simultaneous Dual-Concordant Approach
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CE
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
0.75 program credits
- Kathryn Arbour
0.75 program credits

CME/CE

The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
1.00 program credit
- Richard Lafayette, MD, FACP
1.00 program credit
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
MinuteCE®
Targeting Lower Proteinuria Levels: Shifting the Goalpost in IgAN
1.00 program credit
- Richard Lafayette, MD, FACP
- Suzuki Yusuke, MD, PhD
1.00 program credit
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
- Luciano Costa, M.D., Ph.D.
0.25 credits
RAS Across Tumors: Who to Test When
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits

Clinical Practice

MinuteCE®
Inside the 4 Hits: Targeting APRIL to Change the Course of IgAN
1.00 credit 9 episodes
- Richard Lafayette, MD, FACP
- Dana Rizk, MD
- Hong Zhang
- Suzuki Yusuke, MD, PhD
1.00 credit 9 episodes
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
0.50 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Cristina Rodriguez, MD
0.50 credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
0.75 program credits
- Eileen M. O'Reilly, MD
0.75 program credits
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
0.75 program credits
- Kathryn Arbour
- Eileen M. O'Reilly, MD
0.75 program credits
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CE
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
CME/CE
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
0.25 credits
- María-Victoria Mateos, MD, PhD
0.25 credits

Programs

Mechanism-Based Targeting: Why APRIL Matters in IgAN
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®
Mechanism-Based Targeting: Why APRIL Matters in IgAN
1.00 program credit
- Suzuki Yusuke, MD, PhD
- Dana Rizk, MD
1.00 program credit
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
0.75 program credits
- Eileen M. O'Reilly, MD
- Kathryn Arbour
0.75 program credits
MinuteCE®
From Flare to Farewell: The IBD Care Playbook for Advanced Practice Providers
1.00 credit 9 episodes
- David Rubin, MD
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
- Brooke Hodnick, PA-C, MPAS
1.00 credit 9 episodes
Case Review: Can You Crack This IBD Case? 
Case Review: Can You Crack This IBD Case? 
MinuteCE®
Case Review: Can You Crack This IBD Case? 
1.00 program credit
- David Rubin, MD
- Kimberly D. Orleck, PA-C
1.00 program credit
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
MinuteCE®
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Tailoring Treatment: Can You Select the Best Therapy? 
Tailoring Treatment: Can You Select the Best Therapy? 
MinuteCE®
Tailoring Treatment: Can You Select the Best Therapy? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit

Changing the Practice of Medicine

Popular

CME/CE

Clinical Practice

Programs

Title

Share on ReachMD